ClinicalTrials.gg
RecruitingNCT05583721Updated Nov 18, 2026

Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

A Phase 2 interventional study of [13N]NH3 and Lexiscan in Sickle Cell Disease, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.
Updated Nov 18, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital — 15 open to participants now, 17 under way, none of them phase 3. Anemia, Sickle Cell · St. Jude Children's Research Hospital.

Planned enrollment
13th of 22
40 · median 45
Started
2023
with 2 others
Phase 2
10 of 45
2 open now
Primary completion
2027-09
later than 7 of 16 live
Registered
35th of 45
by date

Among the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, this one is the 13th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2023, is one of 10 in phase 2, reaches primary completion later than 7 of the 16 other live ones, and was the 35th registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

15 of the 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital are open now, in 2 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 21 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Anemia, Sickle Cell by St. Jude Children's Research Hospital, or all of them as a file.
02

Study summary

There is limited information on what causes injury to the heart in individuals with Sickle Cell Disease (SCD). Researchers in this study want to see if decreased blood flow to the heart during stress could be causing the heart damage seen in SCD patients. They also want to test people who don't have SCD to see if their hearts react the same way under stress.

Primary Objective

  • To estimate the coronary flow reserve (CFR) (also referred to as myocardial perfusion reserve), as measured by PET stress-rest myocardial perfusion imaging, in SCD patients with and without diastolic dysfunction, and healthy controls.

Secondary Objectives

  • To investigate the relationship between decreased CFR (quantified with PET stress- rest myocardial perfusion imaging) and presence of abnormal diastolic parameters
Read the detailed description

This study requires two visits. The first visit includes blood tests, an electrocardiogram (EKG), and an echocardiogram. The second visit includes a positron emission tomography (PET) stress test and a blood test.

Subjects will be considered off-study one week after all post PET imaging study tests have been completed along with the next day and one-week follow-up phone calls are completed.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

Keywords

  • Sickle Cell Disease patients
  • Healthy controls
  • Abnormal diastolic heart function
  • Coronary Flow Reserve (CFR)
  • Coronary microvasculature dysfunction
  • Myocardial perfusion reserve
  • Positron emission tomography (PET) imaging
  • PET (stress-rest) myocardial perfusion imaging
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria - Stratum A: Sickle cell patients with diastolic dysfunction

  • 18 to 21 years of age
  • Black
  • Diagnosis of SCD of HbSS and HbSβ0thalassemia genotypes
  • Three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography)

Inclusion Criteria - Stratum B: Sickle cell patients without diastolic dysfunction

  • 18 to 21 years of age
  • Black
  • Diagnosis of SCD of HbSS and HbSβ0thalassemia genotypes
  • Two or less abnormal diastolic parameters

Inclusion Criteria - Stratum C: Healthy controls

  • 18 to 21 years of age
  • Black
  • Two or less abnormal diastolic parameters

Exclusion Criteria - Stratum A:

  • Recent hospitalization for vaso-occlusive pain crisis or acute chest syndrome in last 4 weeks
  • Blood transfusion in the last 3 months
  • Individuals with signs, symptoms or findings of acute myocardial ischemia, infarction or unstable angina
  • Individuals with history of VT/VF or SVT
  • Previous cardiac surgery
  • Known congenital heart disease (other than patent ductus arteriosus or Atrial septal defect)
  • Stenotic valvular disease or left main coronary artery stenosis
  • History of myo/pericarditis
  • Left ventricle systolic dysfunction
  • Cardiovascular instability/uncontrolled hypertension (h/o hypertensive urgency or emergency)
  • History of sinus node dysfunction or high grade AV nodal block
  • History of aborted sudden cardiac death or cardiac arrest
  • Current seizure disorder on AED
  • Pregnant/Breast-feeding
  • Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised.

    • Participant should be able to consent for themselves
    • Participant should be able to follow instruction needed for scans
    • Participant should be able to verbally communicate with study team

Exclusion Criteria - Stratum B:

  • Diagnosed with three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography)
  • Recent hospitalization for vaso-occlusive pain crisis or acute chest syndrome in last 4 weeks
  • Blood transfusion in the last 3 months
  • Individuals with signs, symptoms or EKG findings of acute myocardial ischemia, infarction or unstable angina
  • Individuals with history of VT/VF or SVT
  • Previous cardiac surgery
  • Known congenital heart disease (other than patent ductus arteriosus or Atrial septal defect)
  • Stenotic valvular disease or left main coronary artery stenosis
  • History of myo/pericarditis
  • Left ventricle systolic dysfunction
  • Cardiovascular instability/uncontrolled hypertension (h/o hypertensive urgency or emergency)
  • History of sinus node dysfunction or high-grade AV nodal block
  • History of aborted sudden cardiac death or cardiac arrest
  • Current seizure disorder on AED
  • Pregnant/Breast-feeding
  • Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised.

    • Participant should be able to consent for themselves
    • Participant should be able to follow instruction needed for scans
    • Participant should be able to verbally communicate with study team

Exclusion Criteria - Stratum C:

  • All genotypes of SCD
  • Diagnosed with three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography)
  • Anemia of grade 2 or worse (per v5.0) at study visit 1
  • Individuals with signs, symptoms or EKG findings of acute myocardial ischemia, infarction or unstable angina
  • Individuals with history of VT/VF or SVT
  • Previous cardiac surgery
  • Known congenital heart disease (other than patent ductus arteriosus or Atrial septal defect)
  • Stenotic valvular disease or left main coronary artery stenosis
  • History of myo/pericarditis
  • Left ventricle systolic dysfunction
  • Cardiovascular instability/uncontrolled hypertension (h/o hypertensive urgency or emergency)
  • History of sinus node dysfunction or high-grade AV nodal block
  • History of aborted sudden cardiac death or cardiac arrest
  • Current seizure disorder on AED
  • Pregnant/Breast- feeding
  • Any medical or social reason, which, in the opinion of the principal investigators would make the participation of the subject ill-advised.

    • Participant should be able to consent for themselves
    • Participant should be able to follow instruction needed for scans
    • Participant should be able to verbally communicate with study team
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Stratum A

    Sickle Cell patients with diastolic dysfunction

    Drug: [13N]NH3 · Drug: Lexiscan · Diagnostic Test: Positron emission tomography

  • Experimental
    Stratum B

    Sickle cell patients without diastolic dysfunction

    Drug: [13N]NH3 · Drug: Lexiscan · Diagnostic Test: Positron emission tomography

  • Experimental
    Stratum C

    Healthy controls

    Drug: [13N]NH3 · Drug: Lexiscan · Diagnostic Test: Positron emission tomography

Interventions

  • Drug[13N]NH3

    Ammonia N 13 (a radioactive tracer) will be given per intravenous (IV) injection for diagnostic purposes in conjunction with positron emission tomography (PET) imaging.

    Also known as: [N-13] Ammonia, azane, CAS# 34819-78-8

  • DrugRegadenosonStudies of RegadenosonRegadenoson pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV prior to PET stress test

    Also known as: Regadenoson

  • Diagnostic testPositron emission tomography

    Participants will complete a onetime PET (stress-rest) myocardial perfusion scan.

    Also known as: PET

06

What researchers measure

Primary outcomes

  1. Mean and standard deviation of coronary flow reserve (CFR)

    We will estimate the mean and standard deviation of CFR, as measured by PET myocardial blood flow reserve imaging, in young adult SCD patients with and without diastolic dysfunction and healthy controls.

    Time frame: Visit 2, approximately 4 weeks after study entry (procedure takes approximately one hour)

  2. CFR difference among Stratum A, Stratum B, and Stratum C

    We will compare whether the CFR is different among 3 predefined strata: Stratum A; SCD with diastolic dysfunction patients , Stratum B; SCD without dysfunction patient control, and Stratum C; normal healthy controls by one-way ANOVA or Kruskal-Wallis one-way analysis of variance, depending on the distribution of the data. If the difference exists, the pairwise comparison will be carried out by two sample t test or Wilcoxon rank sum test between two strata.

    Time frame: Visit 2, approximately 4 weeks after study entry (procedure takes approximately one hour)

Secondary outcomes

  1. Relationship between decreased CFR (quantified with PET stress-rest myocardial perfusion imaging) and presence of abnormal diastolic parameters

    The following is the grouping of diastolic parameters used in this study: Group 1: 0 or any 1 diastolic variable abnormal; Group 2: Any 2 variables abnormal; Group 3: Any 3 or more variables abnormal . We will first summarize the mean and standard deviation CFR values for each diastolic group. One-way ANOVA or Kruskal-Wallis one-way ANOVA will be used to explore whether there are any statistically significant differences between the means of these three groups. If a difference exists, the pairwise comparison will be carried out by two sample t test or Wilcoxon rank sum test between two groups.

    Time frame: Visit 2, approximately 4 weeks after study entry (procedure takes approximately one hour)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available at the time of article publication.

Access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Sep 2027, 47 months after the start.

Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 47 months is below that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2022
First posted
Oct 18, 2022
StartActual
Oct 10, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
9 criteria added
What changed in the criteria
  • AddedParticipant should be able to consent for themselves
  • AddedParticipant should be able to follow instruction needed for scans
  • AddedParticipant should be able to verbally communicate with study team
  • AddedParticipant should be able to consent for themselves
  • AddedParticipant should be able to follow instruction needed for scans
  • AddedParticipant should be able to verbally communicate with study team
  • AddedParticipant should be able to consent for themselves
  • AddedParticipant should be able to follow instruction needed for scans
  • AddedParticipant should be able to verbally communicate with study team
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Eligibility 9 criteria added
    What changed in the criteria
    • AddedParticipant should be able to consent for themselves
    • AddedParticipant should be able to follow instruction needed for scans
    • AddedParticipant should be able to verbally communicate with study team
    • AddedParticipant should be able to consent for themselves
    • AddedParticipant should be able to follow instruction needed for scans
    • AddedParticipant should be able to verbally communicate with study team
    • AddedParticipant should be able to consent for themselves
    • AddedParticipant should be able to follow instruction needed for scans
    • AddedParticipant should be able to verbally communicate with study team
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05583721
Responsible party
Sponsor
First posted
Oct 18, 2022
Start date
Oct 10, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Parul Rai, MD
Contact
referralinfo@stjude.org
888-226-4343
Parul Rai, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion